Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00546650 · ClinicalTrials.gov registry record · Phase 1

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

A Phase 1 study of Healthy, sponsored by NuPathe.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT00546650 is a Phase 1 study of Healthy that has completed, run by NuPathe. The registered enrollment target is 25 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00546650, a Phase 1 study of Healthy, has completed, sponsored by NuPathe.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The primary objective is to compare the pharmacokinetics (PK) of NP101 with the currently approved oral, injection and nasal spray formulations of Imitrex® in healthy volunteers and to assess the bioavailability relative to the 6 mg subcutaneous injection. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.

Conditions Studied

Interventions

  • DRUG Sumatriptan succinate

Study Locations (1)

Florida

  • Orlando Clinical Research Center - Orlando

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2007-11
Est. Completion 2008-03
Phase Phase 1

Sponsor

NuPathe

7 total trials

What the Registry Record Tells You About NCT00546650

The ClinicalTrials.gov registry entry for NCT00546650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is NuPathe, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Sumatriptan succinate is the first listed.

NCT00546650 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00546650 about?

NCT00546650 is a clinical study titled "Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®". The primary objective is to compare the pharmacokinetics (PK) of NP101 with the currently approved oral, injection and nasal spray formulations of Imitrex® in healthy volunteers and to assess the bioavailability relative to the 6 mg subcutaneous injection. The secondary objective is to evaluate the...

What is the current status of trial NCT00546650?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-11. Estimated completion is 2008-03.

What conditions does trial NCT00546650 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00546650?

The interventions under investigation include: Sumatriptan succinate (DRUG).

Who is sponsoring clinical trial NCT00546650?

This trial is sponsored by NuPathe, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00546650 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.